AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03580213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand therapy MCPJ affected
Description: Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices.
Study NCT03677323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The patient will have the choice between different environments and the use of this device will remain under the control of the medical team.~The patient will wear the virtual reality device at the time of the completion of the ankle block and will remove it once the nerve puncture is complete.
Study NCT03677323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droleptan
Description: Venous administration of 1.25 mg of Droleptan
Study NCT03580213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand therapy PIPJ affected
Description: Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices. Possible additional splint and exercises specifically for the PIPJ extension.
Study NCT02151019 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT will be given to some patients to enable comparison of the acute grade 2 GI toxicities compared to those patients receiving their radiotherapy by 3-DCRT
Study NCT03677323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Venous administration of 20 mg of Propofol
Study NCT03219203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine (20 µg/ml) 1 ml intramuscular injection in single (at 0 month) or 3-dose series (at 0, 1, 6 months)
Study NCT03219203 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine (20 µg/ml) 1 ml intramuscular injection in single (at 0 month) or 3-dose series (at 0, 1, 6 months)
Study NCT04683289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trabeculotomy
Description: performing partial unroofing of the SC and viscoelastic injection into the 2 ostia of the canal. This was followed by connecting the scalemm canal to the anterior chamber
Study NCT04683289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trabeculotomy
Description: performing partial unroofing of the SC and viscoelastic injection into the 2 ostia of the canal. This was followed by connecting the scalemm canal to the anterior chamber
Study NCT02951351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine
Description: Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.
Study NCT02951351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conjunctival culture
Description: Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.
Study NCT02951351 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conjunctival culture
Description: Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.
Study NCT02792985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation protocol
Description: Participation in occupation-based multisensory stimulation (e.g. personal care with aromatic soaps, varying water temperatures and textured sponges, drink preparation of different flavoured beverages) with a variety of different sensory stimuli (e.g. strong smells, different shapes and weights). The participant will receive two individual 30-minute therapy sessions with an Occupational Therapist.~An enriched environment will be set up in the participant´s bedroom. It will include items that provide a range of meaningful sensory stimuli (e.g. familiar personal objects, projection of photos and known places, familiar music). The participant is encouraged to follow a timetable including regular rest breaks through out the day in their room.
Study NCT02792985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control protocol
Description: Retraining of basic activities of daily living or participation in table top tasks and games in an individual 30 minute session or a one hour small group session with an Occupational Therapist.~Minimal changes are made to the participant´s room (e.g. orientation board, photos of family and friends).
Study NCT03321006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonak Audeo B-R 90 hearing aid device (Active)
Description: Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Full amplification hearing aids will have their gain determined by audiometric profile as per standard clinical practice
Study NCT03321006 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Duloxetine or escitalopram
Description: We opted to allow two potential medication choices so that study participation could be offered to individuals who had previously taken one medication and either not responded or not tolerated it. After 4 weeks if subjects do not meet remission criteria (HRSD≤10), the dose of study medication will be increased to escitalopram 20mg or duloxetine 60mg for the remaining 8 weeks of the study.
Study NCT03321006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine or escitalopram
Description: We opted to allow two potential medication choices so that study participation could be offered to individuals who had previously taken one medication and either not responded or not tolerated it. After 4 weeks if subjects do not meet remission criteria (HRSD≤10), the dose of study medication will be increased to escitalopram 20mg or duloxetine 60mg for the remaining 8 weeks of the study.
Study NCT03321006 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Audeo B-R 90 hearing aid device (Sham)
Description: Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Low amplification hearing aids will be programmed to a hearing threshold of 10dB across all frequencies
Study NCT02095795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technological Rehabilitation
Description: The Lokomat (Hocoma, Zurich, Switzerland) is robotic device conformed as an exoskeleton on the lower limbs of the patient. Through active and passive actuators, it realize a proper trajectory with an associated motion profile of the involved limbs. The results are physically guide repetitive, rhythmic, bilateral lower extremity movements in order to simulate a physiological gait cycle.The system uses a dynamic body weight-support system to support the participant above a motorized treadmill synchronized with the Lokomat. Participants were provided verbal encouragement to actively step in conjunction with the movement presented by the Lokomat.
Study NCT02095795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Rehabilitation
Description: When needed, more than one therapist are employed in the intervention for safety reasons.
Study NCT02508922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2,000iu vitamin D drops will be taken daily for 20 weeks
Study NCT02508922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo drops will be taken daily for 20 weeks
Study NCT02733302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hope theory
Description: Adapted Physical Activity
Study NCT03278886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose naltrexone
Description: 4.5 mg of low dose naltrexone taken once daily for 8 weeks
Study NCT03278886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: 18 mg of nalmefene taken once daily for 8 weeks
Study NCT01864863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1206
Description: One Bosentan 125 mg tablet
Study NCT01864863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traclear
Description: Two Bosentan 62.5 mg tablets
Study NCT03677323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanyl
Description: Venous administration of 5 μg of Sufentanyl.
Study NCT03785912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based self-help
Description: Eight cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of adjustment problems after having an accident.
Study NCT00534885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Healive® Lot 1
Description: Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
Study NCT00534885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Healive® Lot 2
Description: Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
Study NCT00534885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Healive® Lot 3
Description: Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
Study NCT00534885 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: Inactivated hepatitis A vaccine manufactured by GlaxoSmithKline Biologicals; two-dose regimen with 6 months apart
Study NCT03440307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-Face Meetings
Description: Participants received health and fitness education, and a face-to-face 3-week intervention to reduce bisphenol exposure.
Study NCT03440307 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Email Only
Description: Participants received health and fitness education.
Study NCT00039494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00039494 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study NCT00039494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study NCT04525079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P59
Description: CT-P59 will be administered
Study NCT02390843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: The starting dose of simvastatin will be 140 mg/m\^2/dose BID for 21 days for the first group. Dose escalation for subsequent groups will be 180 mg/m\^2/dose BID, 225 mg/m\^2/dose BID, and 290 mg/m\^2/dose BID. If the maximum tolerated dose (MTD) has been exceeded at the first dose level, then the subsequent cohort of subjects will be treated at a dose of 100 mg/m2/dose BID (dose level 0). Simvastatin will be administered orally twice daily, approximately 12 hours apart. Feeding tube (nasogastric tube or gastrostomy tube, NOT a jejunum localized tube) administration is allowed. If a subject vomits a dose of simvastatin, it will not be repeated.
Study NCT02390843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The dose of cyclophosphamide will be fixed at 250 mg/m\^2/dose. Cyclophosphamide will be administered intravenously over 30 minutes once daily for 5 days every 21 days.
Study NCT02390843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: The dose of topotecan will be fixed at 0.75 mg/m\^2/dose. Topotecan will be administered, after cyclophosphamide, intravenously over 30 minutes once daily for 5 days every 21 days.
Study NCT02390843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myeloid growth factor
Description: Myeloid growth factor (G-CSF or pegylated G-CSF) will be initiated 24-48 hours after the completion of topotecan and cyclophosphamide for all subjects, which would be day 6 or 7. Myeloid growth factor should continue until the absolute neutrophil count is greater than 2,000/mm\^3
Study NCT01798186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will be exposed to cannabis smoke present in ambient air
Study NCT01474616 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sit-to-Stand Activity
Description: Health care aides will be expected to prompt residents to repeatedly stand up and sit down on four occasions throughout the day (twice on each of the day and evening shifts). The number of repetitions on each occasion will vary according to residents' ability and fatigue. The sit-to-stand activity is to be integrated into usual care routines such as when entering the dining room at mealtimes, while toileting, and on other occasions of regular activity. The timing and location will be at the discretion of the health care aide.
Study NCT00790153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin infusion given during 3 hours at one occasion.
Study NCT00790153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1656
Description: Single dose oral suspension given at one occasion.
Study NCT02735733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Bakri Balloon
Description: In the room temperature arm, the bakri balloon will be inserted through the vagina and placed inside the uterus and filled with room temperature saline. In the cold arm, the same intervention will performed, however, the bakri balloon will be filled with cold saline at 32 degrees Fahrenheit.
Study NCT02735733 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Bakri Balloon
Description: In the room temperature arm, the bakri balloon will be inserted through the vagina and placed inside the uterus and filled with room temperature saline. In the cold arm, the same intervention will performed, however, the bakri balloon will be filled with cold saline at 32 degrees Fahrenheit.
Study NCT03740880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual trigger
Description: dual trigger: 10.000 IU hCG i.m. and 0.3 mg Deca
Study NCT03740880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual trigger
Description: dual trigger: 10.000 IU hCG i.m. and 0.3 mg Deca
Study NCT01113658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNaP Wound Care System
Description: The intervention is negative pressure wound therapy (NPWT) with the Spiracur SNaP Wound Care system for the treatment of a variety of acute and chronic wounds including pressure ulcers, trauma wounds, diabetic foot ulcers, venous stasis ulcers, and skin grafts.~The Spiracur SNaP Wound Care system weighs less than 4 ounces, does not utilize an electric pump (device has no electrically powered parts), is fully disposable after use, and is designed for particularly small chronic wounds that require advanced wound care management. It delivers NPWT at a constant pressure level over several days without any required adjustments by the patient or clinician.
Study NCT00708305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride (NaF)
Description: Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF
Study NCT00708305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride (NaF)
Description: Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF
Study NCT00708305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fluoride free toothpaste (0ppmF)
Study NCT04711460 — intervention group
Intervention type: BEHAVIORAL
Intervention: Younger participants
Description: Younger Participants 19-29 years received TAU + Tx over 5 weeks
Study NCT04711460 — intervention group
Intervention type: BEHAVIORAL
Intervention: Older participants
Description: older participants 30-54 years received TAU + Tx over 5 weeks
Study NCT04711460 — intervention group
Intervention type: BEHAVIORAL
Intervention: TAU
Description: Participants received TAU or Treatment As Ususal, Cognitive Behavior Therapy only
Study NCT04711460 — intervention group
Intervention type: BEHAVIORAL
Intervention: TAU + MIndfulness practice
Description: Participants received TAU + mindfulness training
Study NCT04942860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Methotrexate gel
Description: 1% methotrexate gel applied onto a predefined limb
Study NCT04942860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% Methotrexate gel
Description: 1% methotrexate gel applied onto a predefined limb
Study NCT04942860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Methotrexate gel
Description: 0.5% methotrexate gel applied onto a predefined limb
Study NCT04942860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.5% Methotrexate gel
Description: 0.5% methotrexate gel applied onto a predefined limb
Study NCT04147182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline 3%
Description: 3% and 5% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. The pH may have been adjusted with hydrochloric acid. It contains no antimicrobial agents.
Study NCT00624325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alfa-2b
Description: 12 MU daily continuously subcutaneous
Study NCT00624325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alfa-2b
Description: 9 MU daily continuously subcutaneous
Study NCT00624325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alfa-2b
Description: 6 MU daily continuously subcutaneous
Study NCT03173781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: droxidopa
Description: medication
Study NCT03173781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: medication
Study NCT02490618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic tablet- Biogaia
Study NCT04525079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching CT-P59
Study NCT01413789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermatix
Description: 1 application of Dermatix
Study NCT01413789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kelocote
Description: 1 application of Kelocote
Study NCT01413789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAP scar gel
Description: 1 application of BAP scar gel
Study NCT01413789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alhydran
Description: 1 application of Alhydran
Study NCT01413789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bap Scar Care T
Description: 1 application of BAP Scar Care T
Study NCT01413789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bap Scar Care S
Description: 1 Application of Bap Scar Care S
Study NCT01413789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepiform
Description: 1 application of Mepiform
Study NCT01413789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scar Ban Elastic
Description: 1 application of Scar Ban Elastic
Study NCT03231540 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplement
Description: Whey protein supplement to target protein intake of 1.5 g/kg/day
Study NCT03819595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise
Description: a free 12-week, small-group (\~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
Study NCT03819595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: a free 12-week, small-group (\~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
Study NCT03819595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Program PVS
Description: a standardized promotion prescription of physical activity, balanced diet and smoking cessation, using the computer tool Promote Healthy Living integrated into the electronic medical record.
Study NCT02490618 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Study NCT00282815 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure or CPAP
Description: RemStar Pro (Respironics, Inc.) The CPAP is applied through a nasal mask during the hours of sleep. Positive air pressure holds the naso-oro-pharyngeal airway open during sleep.
Study NCT00282815 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham CPAP
Description: sham CPAP
Study NCT03239405 — intervention group
Intervention type: DEVICE
Intervention: Suction callibrated system
Description: One-step suction callibrated SG system
Study NCT01921244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Parents will receive an intervention modified from the previously published tool called Autism: Should My Child Take Medicine for Challenging Behavior? This packet provides parents with educational information, elicits parent ratings of particular behavioral domains, describes behaviors that are and are not amenable to medication treatment, and elicits parent preferences regarding treatment. Providers will be trained on use of the intervention in practice to promote shared decision making during clinical encounters.